First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin

Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin

(2017) Shoko Ono et al.   HELICOBACTER

The Superiority of Vonoprazan-based First-line Triple Therapy with Clarithromycin: A Prospective Multi-center Cohort Study on Helicobacter pylori Eradication

(2017) Soichiro Sue et al.   INTERNAL MEDICINE

Randomized clinical trial comparing ten day concomitant and sequential therapies for Helicobacter pylori eradication in a high clarithromycin resistance area

(2016) Sotirios D. Georgopoulos et al.   European Journal of Internal Medicine

Association Between Helicobacter pylori Eradication and Gastric Cancer Incidence: A Systematic Review and Meta-analysis

(2016) Yi-Chia Lee et al.   GASTROENTEROLOGY

Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy forHelicobacter pylorieradication: a phase III, randomised, double-blind study

(2016) Kazunari Murakami et al.   GUT

Role of bismuth in improvingHelicobacter pylorieradication with triple therapy

(2016) Maria Pina Dore et al.   GUT

Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial

(2016) Jyh-Ming Liou et al.   LANCET

Positive penicillin allergy testing results: a systematic review and meta-analysis of papers published from 2010 through 2015

(2016) Farnoush Harandian et al.   POSTGRADUATE MEDICINE

Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects - a randomised open-label cross-over study

(2015) Y. Sakurai et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

The fight against gastric cancer – the IARC Working Group report

(2014) Rolando Herrero et al.   BEST PRACTICE & RESEARCH IN CLINICAL GASTROENTEROLOGY

Eradication of H. pylori Infection in Patients Allergic to Penicillin Using Triple Therapy with a PPI, Metronidazole and Sitafloxacin

(2014) Takahisa Furuta et al.   INTERNAL MEDICINE

Evidence-based recommendations for successfulHelicobacter pyloritreatment

(2014) Jeng-Yih Wu et al.   Expert Review of Gastroenterology & Hepatology

Sitafloxacin-based third-line rescue regimens forHelicobacter pyloriinfection in Japan

(2013) Takahisa Furuta et al.   JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection

(2012) A. G. McNicholl et al.   ALIMENTARY PHARMACOLOGY & THERAPEUTICS

Management ofHelicobacter pyloriinfection—the Maastricht IV/ Florence Consensus Report

(2012) Peter Malfertheiner et al.   GUT

Fifteen-Year Effects of Helicobacter pylori, Garlic, and Vitamin Treatments on Gastric Cancer Incidence and Mortality

(2012) Jun-Ling Ma et al.   JNCI-Journal of the National Cancer Institute

1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine Monofumarate (TAK-438), a Novel and Potent Potassium-Competitive Acid Blocker for the Treatment of Acid-Related Diseases

(2010) Y. Hori et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

“Rescue” regimens after Helicobacter pylori treatment failure

(2008) Javier P Gisbert   WORLD JOURNAL OF GASTROENTEROLOGY